Literature DB >> 18948589

Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma.

Philippe Moreau, Frédéric Garban, Michel Attal, Mauricette Michallet, Gérald Marit, Cyrille Hulin, Lotfi Benboubker, Chantal Doyen, Mohamad Mohty, Ibrahim Yakoub-Agha, Serge Leyvraz, Philippe Casassus, Hervé Avet-Loiseau, Laurent Garderet, Claire Mathiot, Jean-Luc Harousseau.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18948589     DOI： 10.1182/blood-2008-07-168823

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  36 in total

1.  A case of aggressive myeloma recognized shortly after the remission following high-dose chemotherapy with autologous peripheral blood stem cell transplantation.

Authors:  Kaname Ueda; Katsuhiro Miura; Yoshihiro Hatta; Sumiko Kobayashi; Toshitake Tanaka; Atsuko Hojo; Hikaru Ishizuka; Umihiko Sawada; Yoshimasa Kura; Jin Takeuchi
Journal:  Int J Hematol       Date:  2010-08-20       Impact factor: 2.490

2.  Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival.

Authors:  Henk M Lokhorst; Bronno van der Holt; Jan J Cornelissen; Marie José Kersten; Marinus van Oers; Reinier Raymakers; Monique C Minnema; Sonja Zweegman; Gerard Bos; Nicolaas Schaap; Shulamiet Wittebol; Okke de Weerdt; Rianne Ammerlaan; Pieter Sonneveld
Journal:  Haematologica       Date:  2015-09-04       Impact factor: 9.941

3.  Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.

Authors:  Sarah A Holstein; Vera J Suman; Kouros Owzar; Katelyn Santo; Don M Benson; Thomas C Shea; Thomas Martin; Margarida Silverman; Luis Isola; Ravi Vij; Bruce D Cheson; Charles Linker; Kenneth C Anderson; Paul G Richardson; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2020-04-20       Impact factor: 5.742

Review 4.  A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma?

Authors:  Damian J Green; William I Bensinger
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

Review 5.  European perspective on multiple myeloma treatment strategies in 2014.

Authors:  Heinz Ludwig; Pieter Sonneveld; Faith Davies; Joan Bladé; Mario Boccadoro; Michele Cavo; Gareth Morgan; Javier de la Rubia; Michel Delforge; Meletios Dimopoulos; Hermann Einsele; Thierry Facon; Hartmut Goldschmidt; Philippe Moreau; Hareth Nahi; Torben Plesner; Jesús San-Miguel; Roman Hajek; Pia Sondergeld; Antonio Palumbo
Journal:  Oncologist       Date:  2014-07-25

6.  Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma.

Authors:  Luisa Giaccone; Barry Storer; Francesca Patriarca; Marcello Rotta; Roberto Sorasio; Bernardino Allione; Fabrizio Carnevale-Schianca; Moreno Festuccia; Lucia Brunello; Paola Omedè; Sara Bringhen; Massimo Aglietta; Alessandro Levis; Nicola Mordini; Andrea Gallamini; Renato Fanin; Massimo Massaia; Antonio Palumbo; Giovannino Ciccone; Rainer Storb; Ted A Gooley; Mario Boccadoro; Benedetto Bruno
Journal:  Blood       Date:  2011-04-13       Impact factor: 22.113

7.  Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma.

Authors:  F Sahebi; S Iacobelli; A V Biezen; L Volin; P Dreger; M Michallet; P T Ljungman; T de Witte; A Henseler; N P M Schaap; L López-Corral; X Poire; J Passweg; R-M Hamljadi; S H Thomas; S Schonland; G Gahrton; C Morris; N KrÖger; L Garderet
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

Review 8.  [First-line treatment of multiple myeloma].

Authors:  I Breitkreutz; M Raab; H Goldschmidt
Journal:  Internist (Berl)       Date:  2019-01       Impact factor: 0.743

9.  Multiple myeloma: biology, standard therapy, and transplant therapy.

Authors:  Morie A Gertz; Irene Ghobrial; Jean Luc-Harousseau
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

10.  Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.

Authors:  Bart Barlogie; Michel Attal; John Crowley; Frits van Rhee; Jackie Szymonifka; Philippe Moreau; Brian G M Durie; Jean-Luc Harousseau
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.